Colorectal Cancer | Unmet Need | US/EU | 2016
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to cure the disease. Furthermore, some therapies used are associated with side effects that can significantly decrease patients’ quality of life and can also prevent patients from receiving treatment. Hence, there is an unmet need for novel efficacious therapies with an improved safety and tolerability profile, and this Unmet Need module examines the key drivers of prescribing in this indication and analyses significant commercial opportunities.
Related Market Assessment Reports
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
